Pure Global
NCT03510637

Real Life Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt

ANRS 12332 HepNile : Evaluation of Real Life Efficacy and Safety of Antiviral Treatments Including New Direct Antiviral Agents Among Patients Treated for Chronic Hepatitis C (CHC) in Three National Treatment Centres in Cairo
ANRS, Emerging Infectious Diseases·ClinicalTrials.gov
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Hepatitis C
Study type
Observational
Sponsor & location
Primary sponsor
ANRS, Emerging Infectious Diseases
Location
Cairo,Cairo,Cairo, Egypt
Timeline & enrollment
Phase
N/A
Start date
Jan 22, 2018
End date
Aug 01, 2020
Enrollment
7500 participants
Primary outcome

Sustained Virological Response 12 weeks after the end of treatment (SVR12)

Summary

The primary purpose of the ANRS 12332 HepNile study cohort is to assess in Real-Life
 condition the efficacy and the safety profile of new Direct Acting Antivirals (DAAs)
 introduced in the Egyptian National Treatment Programme for the treatment of Chronic
 Hepatitis C (CHC).

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic viral hepatitisOther chronic viral hepatitisChronic hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03510637
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03510637 through Pure Global AI's free database. This phase not specified trial is sponsored by ANRS, Emerging Infectious Diseases and is currently status unknown. The study focuses on Chronic Hepatitis C. Target enrollment is 7500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.